Loading...
Pulmonary Vasodilator Therapy Is Associated with Decreased Mortality in Patients with Chronic Lung Disease and Severe Pulmonary Hypertension
Schanz, Olivia Criner, Gerard J. Rali, Parth Gayen, Shameek
Schanz, Olivia
Criner, Gerard J.
Rali, Parth
Gayen, Shameek
Citations
Altmetric:
Genre
Journal article
Date
2024-03-07
Advisor
Committee member
Department
Thoracic Medicine and Surgery
Permanent link to this record
Collections
Files
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.3390/jcdd11030089
Abstract
The mortality benefit of PAH-specific therapy for patients with pulmonary hypertension (PH) associated with lung disease is not clear. Our aim was to determine whether pulmonary arterial hypertension (PAH)-specific therapy is associated with reduced mortality among all patients with PH associated with lung disease and in patients with chronic lung disease and severe PH. This was a retrospective cohort study of patients at our institution with chronic lung disease and PH. Survival analysis was performed by comparing patients who received PAH-specific therapy with patients who did not receive pulmonary vasodilators in the entire cohort and in a subgroup of patients with severe PH defined as PVR > 5 WU. We identified 783 patients with chronic lung disease and PH; 246 patients met the new criteria for severe PH. In the entire cohort, a similar survival probability was seen between the treated and untreated PH groups (logrank p = 0.67). In the severe PH subgroup, patients treated with PAH-specific therapy had increased survival probability (logrank p = 0.03). PAH-specific therapy was independently and significantly associated with decreased mortality in severe PH (HR 0.31, 95% CI 0.11–0.88, p = 0.03). PAH-specific therapy may confer a mortality benefit in patients with chronic lung disease and severe PH, which is now defined as PVR > 5 WU, similarly to those with pulmonary arterial hypertension.
Description
Citation
Schanz, O.; Criner, G.J.; Rali, P.; Gayen, S. Pulmonary Vasodilator Therapy Is Associated with Decreased Mortality in Patients with Chronic Lung Disease and Severe Pulmonary Hypertension. J. Cardiovasc. Dev. Dis. 2024, 11, 89. https://doi.org/10.3390/jcdd11030089
Citation to related work
MDPI
Has part
Journal of Cardiovascular Development and Disease, Vol. 11, Iss. 3
ADA compliance
Embedded videos
License
Attribution CC BY